Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Tools & Technology › PCR › HeiScreen Preps Liquid Biopsy Breast Cancer Test for Year-End Launch

HeiScreen Preps Liquid Biopsy Breast Cancer Test for Year-End Launch

Mar 12, 2019
|
Justin Petrone
Premium

NEW YORK (GenomeWeb) — HeiScreen, a German molecular diagnostics company, is moving ahead with plans to introduce a liquid biopsy-based test for breast cancer detection for clinical use by the end of the year.

The company's assay relies on a set of 15 methylation and microRNA markers to determine whether a woman has breast cancer. HeiScreen is in the process of obtaining CE-IVD marking for the test with the aim of making it available to German clinicians later in 2019.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Apr
29
Featured Webinar

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
18
Featured Webinar

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.  

What's Popular?

In PCR

  1. With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

    Premium

  2. PerkinElmer Preliminary Q1 Revenues Grow 98 Percent; FDA Issues EUA for PCR COVID-19 Test

  3. Labs Craft SARS-CoV-2 Variant Genotyping Assays for Screening, Surveillance

    Premium

  4. DiaSorin to Acquire Luminex for $1.8B

  5. Armed With $55M in New Funding, Nucleix to Further Invest in Early-Stage Lung Cancer Dx

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.